NVO- this may be old news from last week but while the market for GLP1 based drugs for T2D/Obesity drugs continues to expand on a dollar basis, it is worth noting the price is declining slightly in the US for NVO’s drugs according to the CFO “as volumes and competition have increased...” In the US it is possible that LLY’s Trizepatide is starting to affect what NVO is doing with Ozempic/Wegovy. Or it could be that this could be because of political pressure or because supply issues are being taken care of and the drug is more available with NVO wanting to maximize share. Here is the link:
FWIW- a similar article also appeared around British pricing which indicated that both Mounjaro (from LLY) and Wegovy (from NVO) prices were falling. They indicated the reason was competition between on-line pharmacies, not cuts by the manufacturer so a different reason than the US price decline for Wegovy. Note that Tirzepatide (aka – Mounjaro) has not yet been approved in Europe for Weight loss yet. Mounjaro is for T2D and Wegovy is for weight loss but the drugs are often conflated into being for the same things.). Also worth noting was the price for the starter dose of Mounjaro at 159 pounds ($198) has now gone to 149 pounds ($186) which is unsurprisingly considerably less than the US List price of approx. $1000! Here is the link for that story:
News 
Market Data 
Discover 
